Antiangiogenesis to treat cancer and intraocular neovascular disorders
- 1 March 2007
- journal article
- review article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 87 (3), 227-230
- https://doi.org/10.1038/labinvest.3700526
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Angiogenesis as a therapeutic targetNature, 2005
- Endothelial cells and VEGF in vascular developmentNature, 2005
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- Emerging Roles of Targeted Small Molecule Protein-Tyrosine Kinase Inhibitors in Cancer TherapyOncology Research, 2003
- Photodynamic Therapy With Verteporfin for Choroidal Neovascularization Caused by Age-related Macular DegenerationAmerican Journal of Ophthalmology, 1999
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- Age-Related Macular Degeneration and Blindness due to Neovascular MaculopathyAmerican Journal of Ophthalmology, 1984